AstronauTx is at the forefront of a novel approach to treating neurodegenerative diseases. We have a unique portfolio of small-molecule therapeutics to restore dysregulated physiology to both improve symptoms and modify disease.
Employees: 1-10
Total raised: $61M
Founded date: 2019
Investors 2
| Date | Name | Website |
| 26.10.2023 | MPM Capita... | mpmcapital... |
| - | MPM BioImp... | mpmbioimpa... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 16.10.2023 | Series A | $61M | - |
Mentions in press and media 6
| Date | Title | Description |
| 16.10.2023 | AstronauTx, developing treatments for Alzheimer's, raises $59M Series A | The startup works in partnership with UCL and is backed by Novartis and UK gov't funds In the United States alone, about 10.7% of people age 65 and older are living with Alzheimer's – the most common form of dementia. That number is project... |
| 10.10.2023 | UK-based AstronauTx raises GBP 48 million in Series A | London, United Kingdom-based AstronauTx, a biotech company developing novel treatments for Alzheimer’s disease and other neurodegenerative disorders, raised GBP 48 million (USD 61 million) in Series A financing. The round took place on Octo... |
| 09.10.2023 | AstronauTx Raises £48M in Series A Financing | AstronauTx Ltd, a London, UK-based biotech company, raised£48m ($61m) in Series A financing. The round was led by Novartis Venture Fund, with participation from Brandon Capital, MPM Capital, EQT Life Sciences, Bristol Myers Squibb and found... |
| 09.10.2023 | AstronauTx closes a £48 million ($61 million) Series A financing to create new treatments for Alzheimer’s disease | London UK, XXXX– AstronauTx Ltd. (“AstronauTx”), a biotech company developing novel treatments for Alzheimer’s disease and other neurodegenerative disorders today announced the completion of a £48 million ($61 million) Series A financing.... |
| 09.10.2023 | Novartis-backed AstronauTx heads off for Alzheimer's mission with $61M series A | While the final frontier of Alzheimer’s disease work is patrolled by U.S. Big Pharmas like Eli Lilly and Biogen as well as Japan’s Eisai, the U.K. is sending out its own mission in the form of AstronauTx. The London-based biotech was spun o... |
| 09.10.2023 | - | Brandon Capital Joins AstronauTx’ £48 million ($61 million) Series A Financing to Create New Treatments for Alzheimer’s disease |